BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 35419031)

  • 1. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.
    Wang F; Dong X; Yang F; Xing N
    Front Genet; 2022; 13():831146. PubMed ID: 35419031
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
    Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
    Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing.
    Wang T; Liu Z; Wang X; Bai P; Sun A; Shao Z; Luo R; Wu Z; Zhang K; Li W; Xiao W; Duan B; Wang Y; Chen B; Xing J
    Cancer Biol Ther; 2020 Aug; 21(8):709-716. PubMed ID: 32449441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.
    Silva TA; Azevedo H
    J Proteomics; 2020 Oct; 229():103951. PubMed ID: 32860965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
    Mossanen M; Carvalho FLF; Muralidhar V; Preston MA; Reardon B; Conway JR; Curran C; Freeman D; Sha S; Sonpavde G; Hirsch M; Kibel AS; Van Allen EM; Mouw KW
    Eur Urol; 2022 May; 81(5):466-473. PubMed ID: 34953602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive diagnosis and surveillance of bladder cancer with driver and passenger DNA methylation in a prospective cohort study.
    Xiao Y; Ju L; Qian K; Jin W; Wang G; Zhao Y; Jiang W; Liu N; Wu K; Peng M; Cao R; Li S; Shi H; Gong Y; Zheng H; Liu T; Luo Y; Ma H; Chang L; Li G; Cao X; Tian Y; Xu Z; Yang Z; Shan L; Guo Z; Yao D; Zhou X; Chen X; Guo Z; Liu D; Xu S; Ji C; Yu F; Hong X; Luo J; Cao H; Zhang Y; Wang X
    Clin Transl Med; 2022 Aug; 12(8):e1008. PubMed ID: 35968916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of bladder cancer genomics: What have we learned and how can we use it?
    Audenet F; Attalla K; Sfakianos JP
    Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational Landscape of Bladder Cancer in Mexican Patients:
    Pérez-Montiel MD; Cerrato-Izaguirre D; Sánchez-Pérez Y; Diaz-Chavez J; Cortés-González CC; Rubio JA; Jiménez-Ríos MA; Herrera LA; Scavuzzo A; Meneses-García A; Hernández-Martínez R; Vaca-Paniagua F; Ramírez A; Orozco A; Cantú-de-León D; Prada D
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674608
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Pignot G; Le Goux C; Vacher S; Schnitzler A; Radvanyi F; Allory Y; Lallemand F; Delongchamps NB; Zerbib M; Terris B; Damotte D; Bieche I
    Oncol Lett; 2019 Oct; 18(4):3471-3480. PubMed ID: 31516565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection.
    Rao N; Starrett GJ; Piaskowski ML; Butler KE; Golubeva Y; Yan W; Lawrence SM; Dean M; Garcia-Closas M; Baris D; Johnson A; Schwenn M; Malats N; Real FX; Kogevinas M; Rothman N; Silverman DT; Dyrskjøt L; Buck CB; Koutros S; Prokunina-Olsson L
    Cancer Prev Res (Phila); 2023 Oct; 16(10):561-570. PubMed ID: 37477495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M.
    Sun JX; Xia QD; Zhong XY; Liu Z; Wang SG
    Front Cell Infect Microbiol; 2023; 13():1182322. PubMed ID: 37351184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of TAp63γ and P53 point mutations in regulating DNA repair, mutational susceptibility and invasion of bladder cancer cells.
    Wang HT; Lee HW; Weng MW; Liu Y; Huang WC; Lepor H; Wu XR; Tang MS
    Elife; 2021 Nov; 10():. PubMed ID: 34747697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prognostic immune predictor, HLA-DRA, plays diverse roles in non-muscle invasive and muscle invasive bladder cancer.
    Piao XM; Kang HW; Jeong P; Byun YJ; Lee HY; Kim K; Seo SP; Kim WT; Lee JY; Ha YS; Choi YH; Moon SK; Yun SJ; Kim WJ
    Urol Oncol; 2021 Apr; 39(4):237.e21-237.e29. PubMed ID: 33339725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of
    Yang Z; Shen Z; Jin D; Zhang N; Wang Y; Lei W; Zhang Z; Chen H; Naz F; Xu L; Wang L; Wang S; Su X; Yu C; Li C
    J Clin Transl Res; 2021 Jun; 7(3):386-413. PubMed ID: 34239995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Komura K; Hirosuna K; Tokushige S; Tsujino T; Nishimura K; Ishida M; Hayashi T; Ura A; Ohno T; Yamazaki S; Nakamori K; Kinoshita S; Maenosono R; Ajiro M; Yoshikawa Y; Takai T; Tsutsumi T; Taniguchi K; Tanaka T; Takahara K; Konuma T; Inamoto T; Hirose Y; Ono F; Shiraishi Y; Yoshimi A; Azuma H
    Mol Cancer; 2023 Nov; 22(1):185. PubMed ID: 37980528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative Multi-Omics Analysis for the Determination of Non-Muscle Invasive vs. Muscle Invasive Bladder Cancer: A Pilot Study.
    Yu EY; Zhang H; Fu Y; Chen YT; Tang QY; Liu YX; Zhang YX; Wang SZ; Wesselius A; Li WC; Zeegers MP; Xu B
    Curr Oncol; 2022 Jul; 29(8):5442-5456. PubMed ID: 36005168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic expression changes between non-muscle-invasive bladder cancer and muscle-invasive bladder cancer.
    Zhao YG; Shi BY; Qian YY; Bai HW; Xiao L; He XY
    Tumori; 2014; 100(6):e273-81. PubMed ID: 25688510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
    Groeneveld CS; Sanchez-Quiles V; Dufour F; Shi M; Dingli F; Nicolle R; Chapeaublanc E; Poullet P; Jeffery D; Krucker C; Maillé P; Vacherot F; Vordos D; Benhamou S; Lebret T; Micheau O; Zinovyev A; Loew D; Allory Y; de Reyniès A; Bernard-Pierrot I; Radvanyi F
    Eur Urol; 2024 May; 85(5):483-494. PubMed ID: 37380559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.